1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

22 Nov 2021
Admin
News Article

Zydus Cadila Gets Usfda Nod To Market Generic Cancer Drug In Us

Drug Firm Zydus Cadila OnSaturday Said It Has ReceivedApproval From The Us HealthRegulator To Market DecitabineInjection, Used To Treat CertainTypes Of Cancers, In TheAmerican Market. The CompanyHas Received Final Approval FromThe Us Food And DrugAdministration (Usfda) ToDecitabine For Injection In TheStrength Of 50 Mg/Vial Single-Https://Health.Economictimes.Indiatimes.Com/News/Pharma/Zydus-Cadila-Gets-Usfda-Nod-To-Market-Generic-Cancer-Drug-In-Us/87818957 2/9Importance Of FinancialPlanning For HealthcareIn The Light Of TheNo Scientific Evidence InCountry Underlines NeedFor Covid-19 BoosterSun Pharma Recalls Over1.10 Lakh Bottles OfGeneric Drug In UsCovaxin Offers ProtectionAgainst Multiple Variants:StudyPharma Zydus Cadila Usfda Us Pharma Firms Health News Generic DrugsDose Vial, Zydus Cadila Said In A Statement.Decitabine Is Used To Treat Myelodysplastic Syndromes, Certain Types Of Blood OrBone Marrow Cancer.The Drug Will Be Manufactured At The Group'S Injectables Manufacturing Facility, TheDrug Maker Said.The Zydus Group Now Has 326 Approvals And Has So Far Filed Over 400Abbreviated New Drug Applications (Andas) Since The Commencement Of The FilingProcess In 2003-04, It Added.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!